Overview
CareMetx, a technology-enabled hub services and provider for pharmaceutical and biotechnology manufacturers, announced its acquisition of VirMedica on September 6, 2018.
VirMedica is the industry leader in providing proprietary e-access technology solutions designed to expedite patient access by simplifying, automating, and ultimately accelerating the processes required for patients when accessing specialty therapies.
Significance
“With VirMedica’s market-leading transactions, we have an opportunity to leverage technology to transform the patient access landscape,” said Mark Hansan, President & CEO of CareMetx. “We look forward to further automating patient onboarding processes, providing efficiencies for our clients, and improving speed to therapy for all patients.”
The acquisition creates an opportunity to leverage VirMedica’s electronic benefits verification technology and serve as the “front-end” to patient access ecosystems.
Crosstree’s Role
Crosstree Capital Partners served as exclusive financial advisor to VirMedica.
Latest Deals
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
.V3%20(1).png)
Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
